Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHER 1050
2012-004977-23Phase 3Completed
- Sponsor
- SFJ LungCancer
- Start
- May 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Dacomitinib with Gefitinib (2 arms). Primary endpoint: Progression-Free Survival. Started May 2013; status: completed.
02
Drugs
dacomitinibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2012-004977-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004977-23.